Secoisolariciresinol diglucoside

Drug Profile

Secoisolariciresinol diglucoside

Alternative Names: SDG

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Saskatchewan
  • Class
  • Mechanism of Action Antioxidants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hypercholesterolaemia; Hypertension

Most Recent Events

  • 19 Aug 2003 This compound is still in active development
  • 19 Jun 2003 Preclinical trials in Hypertension in Canada (unspecified route)
  • 21 May 2003 SDG has been licensed to Archer Daniel Midlands worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top